ACE Inhibitors for Diabetic Nephropathy

ACE inhibitors and angiotensin receptor blockers (ARBs) are foundational therapy for diabetic kidney disease — recommended in anyone with diabetes plus hypertension plus albuminuria (UACR ≥30 mg/g). They slow progression of nephropathy by reducing intraglomerular pressure and lowering proteinuria. Trial evidence includes HOPE (ramipril for CV outcomes), RENAAL (losartan for ESRD reduction), and IRMA-2/IDNT (irbesartan for slowing albuminuria progression). Choose ACEi or ARB based on side effect profile — do not combine (ONTARGET trial showed harm). Newer agents (SGLT2 inhibitors, finerenone, GLP-1 RAs) are layered on for additional protection.

Diabetic Nephropathy in Brief

• Most common cause of end-stage renal disease (ESRD) in the US
• Affects 30 to 40 percent of people with diabetes over time
• Progression: hyperfiltration → microalbuminuria → macroalbuminuria → declining eGFR → ESRD
• Defined by persistent UACR ≥30 mg/g and/or eGFR below 60 mL/min/1.73 m²
• Often coexists with retinopathy and neuropathy (microvascular disease)
• Strongly increases cardiovascular mortality

Mechanism of Kidney Protection

• Angiotensin II preferentially constricts the efferent arteriole (downstream of glomerulus)
• This raises intraglomerular pressure and filtration
• In diabetic kidney disease, hyperfiltration drives glomerular injury and protein leakage
• ACE inhibitors and ARBs dilate the efferent arteriole, reducing intraglomerular pressure
• Result: lower albuminuria, slower nephron loss, slower progression to ESRD
• Effect is independent of blood pressure lowering — but BP reduction adds benefit
• Also reduces aldosterone-mediated fibrosis

When to Start

• Diabetes plus hypertension (blood pressure ≥130/80) regardless of albuminuria
• Diabetes plus albuminuria (UACR ≥30 mg/g) regardless of blood pressure
• Reduced eGFR with proteinuria
• Not routinely used in normotensive normoalbuminuric diabetes for primary kidney prevention
• ADA Standards of Care 2024 recommends moderate-dose ACEi or ARB and titration to maximum tolerated dose for albuminuria reduction

Landmark Trials

Drug List

ACE Inhibitors

ARBs

Starting and Titrating

• Start at a moderate dose; titrate to maximum tolerated (or target dose used in trials) for kidney protection
• Check blood pressure response within 2 weeks
• Check serum creatinine and potassium within 1 to 2 weeks of starting or dose change
• A 20 to 30 percent rise in creatinine is expected and acceptable
• Stop and reassess if creatinine doubles or rises more than 30 percent persistently
• Stop and reassess if potassium exceeds 5.5 to 6 mEq/L
• Recheck UACR at 6 to 12 months to confirm albuminuria reduction (a 30 percent reduction is meaningful)

Side Effects

Cough (ACE Inhibitors)

• Affects 10 to 15 percent of users
• Dry, persistent
• From bradykinin accumulation (ACE inhibitors block bradykinin breakdown)
• Can start weeks to months after initiation
• Resolves 1 to 4 weeks after stopping
• Switch to ARB resolves cough while preserving renal benefit

Angioedema

• Rare (about 0.1 to 0.7 percent) but potentially life-threatening
• Swelling of lips, tongue, face, throat
• Can occur years into therapy
• Higher incidence in African American patients
• Stop immediately — medical emergency if airway involvement
• Cross-reactivity to ARBs is lower than previously thought but caution warranted
• Permanent contraindication to ACE inhibitor restart

Hyperkalemia

• Common, especially with CKD, diabetes (hyporeninemic hypoaldosteronism), or potassium-sparing diuretics
• Monitor potassium after starting and dose changes
• Dietary counseling (avoid salt substitutes containing potassium chloride, limit very high-potassium foods if levels rising)
• Adjust other potassium-elevating drugs (spironolactone, eplerenone, NSAIDs, trimethoprim)
• Newer potassium binders (patiromer, sodium zirconium cyclosilicate) allow maintenance of RAAS therapy in patients with hyperkalemia

Acute Kidney Injury (AKI)

• Risk highest with bilateral renal artery stenosis, dehydration, NSAID co-administration
• Initial 20 to 30 percent rise in creatinine is expected and not harmful
• Larger rises warrant hold and evaluation
• Hold during acute illness with dehydration (“sick day” rules)

Hypotension

• First-dose hypotension possible — start at lower dose in elderly, volume-depleted, on diuretics
• Lightheadedness with standing — adjust diuretic dose

Pregnancy

• Contraindicated — fetotoxic in second and third trimester (oligohydramnios, lung hypoplasia, renal dysplasia, skull hypoplasia)
• Discontinue before conception when possible
• Use methyldopa, labetalol, nifedipine, or hydralazine for hypertension in pregnancy

Layered Kidney Protection

SGLT2 Inhibitors

• EMPA-KIDNEY (empagliflozin), DAPA-CKD (dapagliflozin), CREDENCE (canagliflozin) — all showed reduction in kidney failure progression added to ACEi/ARB
• Use eGFR thresholds per drug — many can now be started down to eGFR 20 to 25 mL/min/1.73 m²
• Modest A1C, BP, weight, uric acid effects
• DKA caution (rare; higher with insulin-deficient patients or perioperative)
• Genital mycotic infections (more common in women)

Finerenone

• Non-steroidal selective mineralocorticoid receptor antagonist
• FIDELIO-DKD and FIGARO-DKD trials showed kidney and CV benefit in T2D with CKD on ACEi/ARB
• Lower hyperkalemia risk than spironolactone
• Monitor potassium

GLP-1 Receptor Agonists

• FLOW trial (semaglutide) showed kidney outcomes benefit in T2D with CKD
• Weight loss, BP, CV benefits also
• Layered on ACEi/ARB plus SGLT2 inhibitor as appropriate

Blood Pressure Targets

• ADA: below 130/80 for most adults with diabetes
• Below 140/90 may be acceptable in older or frail patients
• Home BP monitoring useful
• Multi-drug therapy often needed — add long-acting CCB (amlodipine) or thiazide-like diuretic (chlorthalidone, indapamide) as second agent

Sick Day Rules

• Hold ACEi/ARB, SGLT2 inhibitor, metformin, and NSAIDs during acute illness with vomiting, diarrhea, fever, or significant dehydration
• Resume once oral intake recovers and clinically improved
• Communicate with clinician for guidance
• Update sick day plan annually

Monitoring Schedule

Special Populations

Type 1 Diabetes

• ACE inhibitors recommended for any microalbuminuria, even normotensive
• EUCLID and other early trials support this

Older Adults

• Start at lower doses
• Monitor for hypotension, AKI, hyperkalemia
• Address polypharmacy (NSAIDs, diuretics, K-sparing agents)

African American Patients

• Slightly higher angioedema risk with ACE inhibitors
• BP response often better when combined with a CCB or thiazide
• ARBs are reasonable alternatives

When to Refer to Nephrology

• eGFR below 30 mL/min/1.73 m²
• Rapidly declining eGFR (more than 5 mL/min/year)
• Severe albuminuria (UACR > 300 mg/g)
• Refractory hyperkalemia
• Difficult-to-control hypertension
• Suspected non-diabetic kidney disease (active urine sediment, sudden onset, unusual presentation)
• Anemia of CKD, mineral-bone disorder, or other complications of advancing CKD
• Planning for kidney replacement therapy (dialysis, transplant)

Related Reading

See our overviews on treatment options, diabetes and hypertension, and complications and related conditions. The KDIGO Clinical Practice Guideline for Diabetes Management in CKD outlines layered kidney protection strategies.

The Bottom Line

ACE inhibitors and ARBs are foundational therapy for diabetic kidney disease — they reduce intraglomerular pressure, slow progression to ESRD, lower albuminuria, and protect against cardiovascular events. Trial evidence includes HOPE (ramipril), RENAAL (losartan), and IRMA-2/IDNT (irbesartan). Use one — not both together (ONTARGET showed harm from combination). Cough is the most common ACEi side effect (switch to ARB if bothersome); angioedema is rare but a medical emergency. Monitor potassium and creatinine after starting and dose changes. Layer SGLT2 inhibitors (EMPA-KIDNEY, DAPA-CKD, CREDENCE), finerenone (FIDELIO-DKD), and GLP-1 receptor agonists for additional kidney protection. Hold during acute illness (“sick day” rules) and avoid in pregnancy. Talk to your doctor about starting or optimizing RAAS therapy if you have diabetes and albuminuria or hypertension.